Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 671281, 9 pages
http://dx.doi.org/10.1155/2013/671281
Research Article

Ixeris dentata NAKAI Reduces Clinical Score and HIF-1 Expression in Experimental Colitis in Mice

1Department of Oriental Pharmacy, College of Pharmacy, Wonkwang-Oriental Medicines Research Institute, Wonkwang University, Iksan, Jeonbuk 570-749, Republic of Korea
2Department of Pharmacology, College of Korean Medicine, Institute of Korean Medicine, Kyung Hee University, Dongdaemun-gu, Seoul 130-701, Republic of Korea
3Department of Anatomy and Histology, College of Oriental Medicine, Daegu Hanny University, Yugok-Dong, Kyungsan 712-715, Republic of Korea
4Department of Cosmeceutical Science, Daegu Hanny University, Yugok-Dong, Kyungsan 712-715, Republic of Korea
5Isotope Sciences Lab, Korea Atomic Energy Research Institute, 1266 Shinjeong-dong, Jeongeup, Jeonbuk 580-185, Republic of Korea
6Department of Medicinal Herb, Gyeongju University, Gyeongbuk 780-712, Republic of Korea
7Department of Biochemistry, School of Medicine, Wonkwang University, Iksan, Chonbuk 570-749, Republic of Korea
8Department of Herbology, College of Oriental Medicine, Wonkwang University, Iksan 570-749, Republic of Korea

Received 2 April 2013; Accepted 7 August 2013

Academic Editor: Seong-Gyu Ko

Copyright © 2013 Dae-Seung Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Ixeris dentata (ID) is an herbal medicine used in Asian countries to treat indigestion, pneumonia, hepatitis, contusions, and tumors; however, its effect on intestinal inflammation is unknown. Thus, we investigated the effect of ID in the dextran sulfate sodium (DSS) model of colitis in female BALB/c mice; animals were evaluated after seven days of DSS treatment. DSS-treated mice showed considerable clinical signs, including weight loss, reduced colon length, colonic epithelial injury, infiltration of inflammatory cells in the colon tissue, and upregulation of inflammatory mediators. However, administration of ID attenuated body weight loss, colon shortening, and the increase in disease activity index score. ID also significantly decreased the colonic mucosal injury and the number of infiltrating mast cells. Moreover, ID inhibited the expressions of cyclooxygenase-2 and hypoxia-inducible factor-1α in colon tissue. Taken together, the results provide experimental evidence that ID might be a useful therapy for patients with ulcerative colitis.